NDRG1 Rekombinanter Antikörper

NDRG1 Rekombinant Antikörper für WB, IHC, FC (Intra), IP, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus, Ratte

Anwendung

WB, IHC, FC (Intra), IP, ELISA

Konjugation

Unkonjugiert

CloneNo.

242322F7

Kat-Nr. : 85141-4-RR

Synonyme

242322F7, CMT4D, Differentiation-related gene 1 protein, DRG1, DRG-1

---

• 

  WB analysis using 85141-4-RR

  Various lysates were subjected to SDS PAGE followed by western blot with 85141-4-RR (NDRG1 antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours.

• 

  IP experiment of HeLa using 85141-4-RR

  IP result of anti-NDRG1 (IP:85141-4-RR, 4ug; Detection:85141-4-RR 1:1000) with HeLa cells lysate 1520 ug.

• 

  IHC staining of human lung cancer using 85141-4-RR

  Immunohistochemical analysis of paraffin-embedded human lung cancer tissue slide using 85141-4-RR (NDRG1 antibody) at dilution of 1:400 (under 20x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human lung cancer using 85141-4-RR

  Immunohistochemical analysis of paraffin-embedded human lung cancer tissue slide using 85141-4-RR (NDRG1 antibody) at dilution of 1:400 (under 20x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  FC experiment of HeLa using 85141-4-RR

  1x10^6 HeLa cells were intracellularly stained with 0.25 ug NDRG1 Recombinant antibody (85141-4-RR, Clone:242322F7) and CoraLite®488-Conjugated Goat Anti-Rabbit IgG(H+L) (SA00013-2)(red), or 0.25 ug Rabbit IgG Isotype Control RecAb (98136-1-RR, Clone: 240953C9) (blue). Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).

• 

  Affinity and Kinetic Characterization of 85141-4-RR

  Biolayer interferometry (BLl) kinetic assays of 85141-4-RR against Human NDRG1 were performed. The affinity constant is below 1 pM.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: HeLa-Zellen, A431-Zellen, A549-Zellen, HEK-293-Zellen, Maushirngewebe, Mausnierengewebe
• Erfolgreiche IP: HeLa-Zellen
• Erfolgreiche Detektion in IHC: humanes Lungenkarzinomgewebe; Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen.
• Erfolgreiche Detektion in FC (Intra): HeLa-Zellen

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:5000-1:50000
• Immunpräzipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
• Immunhistochemie (IHC): IHC : 1:200-1:800
• Durchflusszytometrie (FC) (INTRA): FC (INTRA) : 0.25 ug per 10^6 cells in a 100 µl suspension

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Produktinformation

85141-4-RR bindet in WB, IHC, FC (Intra), IP, ELISA NDRG1 und zeigt Reaktivität mit human, Maus, Ratten

• Getestete Reaktivität: human, Maus, Ratte
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Rekombinant
• Typ: Antikörper
• Immunogen: NDRG1 fusion protein Ag25424
• Vollständiger Name: N-myc downstream regulated 1
• Berechnetes Molekulargewicht: 43 kDa
• Beobachtetes Molekulargewicht: 45-46 kDa
• GenBank-Zugangsnummer: BC006260
• Gene symbol: NDRG1
• Gene ID (NCBI): 10397
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Protein-A-Reinigung
• Lagerungspuffer: PBS with 0.02% sodium azide and 50% glycerol
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

NDRG1 is a member of the N-myc down-regulated gene family which belongs to the alpha/beta hydrolase superfamily. NDRG1 is a highly conserved cytoplasmic protein involved in cell growth arrest and proliferation, cell differentiation, DNA damage response, heavy metal response, the hypoxia response, tumorigenesis, and metastasis. NDRG1 is a potent metastasis suppressor in multiple tumor-types. NDRG1 appears to serve as a putative tumor suppressor and is down-regulated in colorectal, gastric, cervical, ovarian and prostate cancers.